Allott EH, et al. - Researchers assessed geographic variations in the incidence of histologic prostate inflammation and subsequent prostate cancer (PC) risk in non-Hispanic white men enrolled in the REDUCE trial from Europe, North America, South America, and Australia/New Zealand. They used multivariable logistic regression to assess links between region and prostate inflammation and between region and PC risk at 2-year biopsy. Regional variations were noted in the prevalence of histologic prostate inflammation. Higher prevalence of acute inflammation, but a lower PC risk, was noted in North America and Australia/New Zealand vs Europe. Geographic differences in prostate inflammation tracked inversely with geographic differences in PC risk.